Plain-English translation of NCT06167785 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether and —two medications that work in different ways to fight cancer—can help people whose lymphoma has returned or stopped responding to CAR-T cell therapy. The trial starts by testing each medication on its own to make sure it's safe, then, if results are good, tests them together. You would receive the medication as either an infusion (injection) or a pill, depending on which treatment arm you're in.
People whose lymphoma comes back after CAR-T therapy have very few treatment options left, and their cancer is often harder to treat. This trial is exploring whether this new combination of medications might offer hope when other treatments have failed.
You likely qualify if…
You likely don't qualify if…
The trial has two phases. First, a small safety phase tests one medication at a time in a handful of patients to ensure it's safe. If that goes well, the trial expands and you would receive both medications together—one as an injection every 3 weeks and one as a twice-daily pill. You would continue treatment as long as the medication is working and you're not having serious side effects, with regular doctor visits to monitor your health and check how your cancer is responding.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
Canada
Phase
Testing effectiveness
Sponsor
University Health Network, Toronto
Enrollment target
~76 participants
Started
June 2025
Primary completion
April 2029
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
John Kuruvilla, FRCPC
University Health Network, Toronto
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.